Boundless Bio, Inc. (NASDAQ:BOLD)
| Market Cap | 59.22M+100.2% |
| Revenue (ttm) | 0 |
| Net Income | -64.01M+0.6% |
| EPS | -2.86+4.3% |
| Shares Out | 22.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,961.605 |
| Open | 2.63 |
| Previous Close | 2.64 |
| Day's Range | 2.56 - 2.67 |
| 52-Week Range | 0.96 - 3.16 |
| Beta | 0.38 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BOLD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BOLD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BOLD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BOLD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BOLD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Facilities related | $6.72M | 48.16% |
| Professional service fees | $2.27M | 16.24% |
| Outsourced services & Consulting | $2.20M | 15.77% |
| Clinical trial costs | $1.33M | 9.54% |
| Interest and other income, net | $691.00K | 4.95% |
| Other costs | $542.00K | 3.88% |
| Insurance | $136.00K | 0.97% |
| Lab and pharmacology supplies | $67.00K | 0.48% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BOLD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BOLD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BOLD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.25M |
| VXFVanguard Extended Market ETF | $427.15K |
| IWCiShares Micro-Cap ETF | $147.19K |
Estimated from each fund’s disclosed top holdings × AUM
BOLD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BOLD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score